Abstract: The invention provides wound treatment compositions comprising from 10.sup.-6 % to 1.0% w/w of one or more peptides, wherein the peptides are from 3 to 30 amino acid residues long and comprise the sequence Gly-Pro-Ala. Preferably, the peptides comprise the sequence Gly-Pro-Ala-Gly, more preferably at the N-terminus. The peptides exhibit a chemotactic effect towards fibroblasts.

Abstract: A peptidomimetic of the turn in the helix-turn-helix (HTH) motif of DNA-binding proteins was designed and synthesized. Conformational constraint was achieved by an unusual linking of two amino acids with a side-chain carbon--carbon bond. A phenyl ring provides the potential for new hydrophobic contacts with the hydrophobic core of the HTH motif. In the mimic, the peptide backbone and the central residue were retained in native form within a 12-membered cyclic tripeptide. The target compound 1b was synthesized by two sequential Horner-Wittig couplings followed by enantioselective hydrogenation with Rh(MeDuPHOS) in 8 steps and 35% overall yield. The stereochemical outcome of the key hydrogenation was determined by aromatic ring oxidation with RuO.sub.2 /NalO.sub.4 to give two equivalents of Boc-Asp-OMe.

Abstract: This invention provides novel radiopharmaceuticals that are radiolabeled cyclic compounds containing carbocyclic or heterocyclic ring systems which act as antagonists of the platelet glycoprotein IIb/IIIa complex; to methods of using said radiopharmaceuticals as imaging agents for the diagnosis of arterial and venous thrombi; to novel reagents for the preparation of said radiopharmaceuticals; and to kits comprising said reagents.

Abstract: The present invention relates to a peptide of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represents SO.sub.3 H or H; X represents an .alpha.-amino acid or a single bond; Z.sup.1 and Z.sup.2 are the same or different and each represents an .alpha.-amino acid; and Y represents OH or NH.sub.2. This peptide has plant growth factor properties.

Abstract: The use of glucagon as a metabolic conditioner for dairy cows and other ruminants is described. The glucagon is preferably administered in an amount of from 1-10 mg per day, preferably during the time period beginning 7 days before calving and continuing until 21 days after calving. The administration of glucagon decreases the incidence of metabolic diseases and metabolic imbalances associated with fatty liver, allows cows to reach peak mile production sooner, and results in increased feed intake during the early stages of lactation.

Abstract: A depsipeptide containing N-substituted glycine residue having the formula (1) or (2): ##STR1## (wherein R.sub.1 is a straight or branched alkyl group of 5-20 carbon atoms or a straight or branched alkoxymethyl group of 5-15 carbon atoms; R.sub.2 is a group of the formula --A--B--W--(D).sub.m --(E).sub.n, --A--B--W--(D).sub.m --(E).sub.n --F or --A--B--W--(D).sub.m --(E).sub.n --F--Z; R.sub.3 is a hydroxyl group, a lower alkoxy group, a benzyloxy group, or a group of the formula --Z, --Z--G or --Z--G--J; A, B, D, E, F, G and J independently are an N-substituted glycine residue or a residue of an amino acid selected from the group consisting of alanine, valine, leucine, serine, etc.; W and Z independently are a residue of an amino acid selected from the group consisting of an aspartic acid, a glutamic acid, etc.; at least one of A, B, D, E, F, G and J is an N-substituted glycine residue) or a pharmacologically acceptable salt thereof.

Abstract: Substantially pure conotoxin peptides are provided which inhibit synaptic transmissions at the neuromuscular junctions and which are useful both in vivo and in assays because they specifically target particular skeletal nAChRs to the exclusion of neuronal nAChRs. The peptides are of such length that they can be made by chemical synthesis, and the preferred peptides have formula: H-His-4Hyp-4Hyp-Cys-Cys-Leu-Tyr-Gly-Lys-Cys-Arg-Arg-Tyr-4Hyp-Gly-Cys-Ser-S er-Ala-Ser-Cys-Cys-Gln-Xaa.sub.24 -NH.sub.2 wherein Xaa.sub.24 is Arg or Gly.

Abstract: In the process for the agglomeration of slightly soluble and hydrolytically sensitive substances, a powder of the slightly soluble substance is conducted, together with at least one water-soluble binder, in free fall through a steam atmosphere at temperatures between 85.degree. C. and 105.degree. C. essentially without the action of compacting forces. In this process, the residence time in the steam atmosphere is approximately 0.5 to 10 seconds. The agglomerates formed are then dried in free fall, so that small solid bridges form from the binder liquid bridges formed at the points of contact between the primary particles. In a following integrated fluidized-bed dryer, the final drying then takes place to a water content of less than 0.5% by weight. The process is carried out in a steam jet agglomerator in which a freely falling product curtain of the pulverulent mixture to be agglomerated is impinged by steam using steam jet nozzles (5, 6).

Abstract: The present invention relates to a novel antimicrobial peptide isolated from Bufo bufo gargarizans exhibiting therapeutic antibacterial and antifungal properties.

Abstract: A pharmaceutically-acceptable aqueous solution which is isobaric or hyperbaric, and isotonic, with respect to cerebrospinal fluid (CSF), comprises a 1-alkyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide anesthetic agent such as bupivacaine or levobupivacaine and a saccharide. If the amount of the anesthetic agent is no more than 0.75% w/v, a salt or another additional non-saccharide is present. Accordingly, the amount of the saccharide can be kept below that which would provide isotonicity in the absence of the additional non-saccharide.

Abstract: The invention concerns a liquid gonadotropin-containing formulation characterised in that the formulation comprises a gonadotropin and stabilising amounts of a polycarboxylic acid or a salt thereof and of a thioether compound. The particular proteins (e.g. LH, TSH, FSH, or HCG) are in admixture with the particular stabilizers in an aqueous solution. The preparations contain a sufficient amount of the polycarboxylic acid or a salt thereof, preferably sodium citrate, and a sufficient amount of the thioether compound, preferably methionine, to stabilize the protein. The preparations preferably also include a nonreducing disaccharide like sucrose, and a non-ionic surfactant.

Abstract: Object: To provide a cyclic hexapeptide compound having a distinguished pharmaceutical effect.Constitution: A cyclic hexapeptide compound represented by the following formula: ##STR1## where R is a group represented by the following formula: ##STR2## (where R.sup.1 and R.sup.2 are each an alkyl group, a phenyl group or a benzyl group) or a group represented by the following formula: ##STR3## (where n is an integer of 4 to 6), or its salts.

Abstract: In the process for the agglomeration of slightly soluble and hydrolytically sensitive substances, a powder of the slightly soluble substance is conducted, together with at least one water-soluble binder, in free fall through a steam atmosphere at temperatures between 85.degree. C. and 105.degree. C. essentially without the action of compacting forces. In this process, the residence time in the steam atmosphere is approximately 0.5 to 10 seconds. The agglomerates formed are then dried in free fall, so that small solid bridges form from the binder liquid bridges formed at the points of contact between the primary particles. In a following integrated fluidized-bed dryer, the final drying then takes place to a water content of less than 0.5% by weight. The process is carried out in a steam jet agglomerator in which a freely falling product curtain of the pulverulent mixture to be agglomerated is impinged by steam using steam jet nozzles (5, 6).

Abstract: The present invention provides cyclic peptides having broad spectrum antimicrobial activity. The peptides exhibit improved efficacy, bioavailability and/or serum half-life as compared with non-cyclized analogues.

Abstract: The present invention is a process for the manufacture of gelatin which includes providing a collagen containing material and demineralizing the collagen containing material to produce ossein. The ossein is added to a water solution containing at least 3% sodium hydroxide or potassium hydroxide and at least 3% sodium sulfate for a time sufficient to form a reacted slurry. The reacted slurry is heated to a temperature of at least 45.degree. C. for a time sufficient to solubilize the ossein thereby producing a solution containing gelatin. The pH of the solution containing gelatin is raised to greater than 9.8. The pH of the solution containing gelatin is reduced with a sulfate salt of a divalent or trivalent metal to a neutral pH (between 7.0 and 8.0). The pH of the gelatin solution is then lowered to between 5.0 and 6.0 and a polymeric flocculant is added to the gelatin solution in an amount of less than 0.1% based on the dry weight of the gelatin to form a floc and the floc is removed.